SecSonar.com

Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Capricor Therapeutics, Inc. (CAPR) is a Biotechnology company based in US with a market capitalization of $1.4B. Free cash flow was negative at -$72.7B. This page tracks CAPR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 160 employees · IPO Feb 13, 2007

Valuation

Valuation & price

$28.79 · as of May 17, 2026 · -18.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.47

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$35.27$19.94$4.60Jul 25Dec 25Jul 26Jul 7, 25$9.90Jul 9, 25$11.42Jul 11, 25$7.64Jul 15, 25$7.18Jul 17, 25$7.16Jul 21, 25$6.27Jul 23, 25$6.82Jul 25, 25$7.06Jul 29, 25$6.74Jul 31, 25$8.18Aug 4, 25$7.68Aug 6, 25$7.74Aug 11, 25$7.82Aug 13, 25$8.30Aug 15, 25$7.96Aug 19, 25$7.67Aug 21, 25$7.02Aug 25, 25$6.60Aug 27, 25$6.25Aug 29, 25$6.28Sep 3, 25$6.28Sep 5, 25$6.74Sep 9, 25$6.48Sep 11, 25$6.44Sep 16, 25$6.22Sep 18, 25$6.40Sep 22, 25$6.09Sep 24, 25$6.19Sep 26, 25$7.09Sep 30, 25$7.21Oct 2, 25$7.97Oct 6, 25$7.81Oct 8, 25$7.48Oct 10, 25$7.09Oct 14, 25$6.70Oct 16, 25$6.16Oct 21, 25$6.37Oct 23, 25$6.13Oct 27, 25$6.18Oct 29, 25$6.92Oct 31, 25$6.51Nov 4, 25$6.06Nov 6, 25$6.28Nov 10, 25$5.56Nov 12, 25$5.87Nov 14, 25$5.60Nov 18, 25$5.64Nov 20, 25$5.69Nov 25, 25$4.60Nov 28, 25$5.35Dec 2, 25$6.36Dec 4, 25$25.40Dec 8, 25$28.56Dec 10, 25$28.67Dec 12, 25$26.02Dec 16, 25$26.02Dec 18, 25$26.19Dec 22, 25$29.50Dec 24, 25$29.68Dec 29, 25$30.04Jan 2, 26$28.31Jan 6, 26$26.13Jan 8, 26$25.55Jan 12, 26$24.51Jan 14, 26$24.79Jan 16, 26$24.35Jan 21, 26$24.31Jan 23, 26$23.20Jan 27, 26$23.52Jan 29, 26$22.61Feb 2, 26$23.09Feb 4, 26$24.50Feb 9, 26$25.19Feb 11, 26$24.20Feb 13, 26$22.45Feb 18, 26$25.53Feb 20, 26$28.51Feb 24, 26$27.91Feb 26, 26$27.89Mar 2, 26$26.86Mar 4, 26$25.50Mar 6, 26$27.90Mar 10, 26$33.40Mar 12, 26$33.42Mar 17, 26$31.19Mar 19, 26$31.17Mar 23, 26$30.10Mar 25, 26$29.90Mar 27, 26$28.90Mar 31, 26$30.40Apr 2, 26$32.11Apr 7, 26$31.97Apr 9, 26$31.61Apr 13, 26$34.54Apr 15, 26$35.04Apr 17, 26$34.70Apr 22, 26$35.00Apr 24, 26$35.27Apr 28, 26$33.98Apr 30, 26$33.58May 4, 26$33.50May 6, 26$34.38May 8, 26$30.38May 12, 26$31.52May 14, 26$29.81May 18, 26$28.02May 20, 26$29.01May 22, 26$28.87May 28, 26$29.11Jun 1, 26$28.53Jun 3, 26$27.64Jun 5, 26$26.71Jun 9, 26$26.01Jun 11, 26$25.04Jun 15, 26$26.72Jun 17, 26$27.95Jun 22, 26$29.34Jun 24, 26$29.51Jun 26, 26$26.44Jul 2, 26$23.21
$4.6052-week range$35.34
Loading valuation history…

Fundamentals

Key fundamentals

$1.4B

Market cap

—

Revenue growth (YoY)

-124.4%

Gross margin

-$72.7B

Free cash flow (USD)

-$297.2M

Net debt

Net cash position

32.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$3.2MFY 2017$2.7MFY 2018$1.7MFY 2019$1.0MFY 2020$310.3KFY 2021$244.9KFY 2022$2.6MFY 2023$25.2MFY 2024$22.3MFY 2025$0.00
$3.2M$0

Free cash flow by year

2016 → 2025

FY 2016$-16.0MFY 2017$-14.3MFY 2018$-14.2MFY 2019$-6.8MFY 2020$-10.6MFY 2021$-18.0MFY 2022$1.6MFY 2023$-27.6MFY 2024$-41.5MFY 2025$-72.7B
-$16M-$72.7B

Gross margin by year

2021 → 2024

FY 2021100.0%FY 2022-755.1%FY 2023-44.8%FY 2024-124.4%
100.0%-124.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $732K · 10b5-1 PlanBergmann Anthony · CHIEF FINANCIAL OFFICER · $732.2KJun 29, 2026Filing
  • Insider sellInsider Sell $732K · 10b5-1 PlanKrasney Karen · EVP, GENERAL COUNSEL · $732.2KJun 29, 2026Filing
  • 8-K eventFDA Advisory Committee MeetingJun 26, 2026Filing
  • Insider sellInsider Sell $27K · 10b5-1 PlanBergmann Anthony · CHIEF FINANCIAL OFFICER · $27KJun 24, 2026Filing
  • Insider sellInsider Sell $27K · 10b5-1 PlanKrasney Karen · EVP, GENERAL COUNSEL · $27KJun 24, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 8, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • 8-K eventLegal Action FiledMay 7, 2026Filing
  • Insider sellInsider Sell $793K · 10b5-1 PlanBergmann Anthony · CHIEF FINANCIAL OFFICER · $792.5KMay 4, 2026Filing

Questions

Frequently asked questions

What is Capricor Therapeutics, Inc.'s market cap?

Capricor Therapeutics, Inc. (CAPR) has a market capitalization of $1.4B.

What is CAPR's P/E ratio?

A meaningful P/E ratio is not available for CAPR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CAPR's price-to-book (P/B) ratio?

CAPR trades at 4.47 times book value per share.

Are insiders buying CAPR stock?

SEC Form 4 filings show no open-market insider buys at Capricor Therapeutics, Inc. in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

URGN

UroGen Pharma Ltd.

$1.4B

SEPN

Septerna, Inc.

$1.4B

MRVI

Maravai LifeSciences Holdings, Inc.

$1.3B

PGEN

Precigen, Inc.

$1.3B

IOVA

Iovance Biotherapeutics, Inc.

$1.4B

WVE

Wave Life Sciences Ltd.

$1.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.